Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1990-12-27
|
| pubmed:abstractText |
E mu-myc transgenic mice were back-crossed to BALB/c mice up to back-cross generation 3. The offspring that included transgene-carrying and -negative mice in approximately equal proportions were randomly divided into 2 groups. Thirty-four mice (group I) were treated with pristane, followed by A-MuLV, and 40 (group II) were injected with A-MuLV alone. Altogether, 16 lymphoid tumors developed in group I and 17 in group II. Nine of the tumors in group I and 4 in group II appeared as ascitic tumors. The ascites contained lymphoblasts and 10 to 45% plasmacytoid cells. These tumors were designated as plasmablastic lymphomas (PLs). All tumors except one were transgene-positive and did not carry translocations. An exceptional tumor in group I carried a variant 6;15 translocation but not the transgene. It obviously corresponds to the regular Abelson + pristane-induced plasmacytoma. Among 11 tested PLs, 10 had a single retroviral insertion site, while one tumor showed 3. Among 18 untreated transgenic descendants (group III), chosen randomly during serial back-crosses, 15 (83%) developed lymphomas, with no sign of plasmacytoid differentiation. The incidence was comparable in all 3 groups, assuming 50% of the mice in groups I and II to be transgenic. The time distribution of tumor development was also similar. Spleen cells from transgene-carrying mice with no clinical sign of lymphoma were infected in vitro with A-MuLV and transplanted i.p. into BALB/c recipients. PLs developed in 26 of 31 pristane-treated recipients, but in only one of 18 untreated recipients. One of 6 PLs tested was monoclonal, whereas the remaining 5 were oligoclonal. They all expressed v-abl. These results show that some of the preneoplastic B-cells that expressed constitutively active myc transgene turned into plasmablasts after infection with A-MuLV. Full development of their neoplastic potential was facilitated by the presence of pristane-granuloma.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0020-7136
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
46
|
| pubmed:geneSymbol |
E&mgr;-myc
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
845-52
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:2228313-Animals,
pubmed-meshheading:2228313-B-Lymphocytes,
pubmed-meshheading:2228313-Carcinogens,
pubmed-meshheading:2228313-Cell Transformation, Neoplastic,
pubmed-meshheading:2228313-Cell Transformation, Viral,
pubmed-meshheading:2228313-Female,
pubmed-meshheading:2228313-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:2228313-Genes, myc,
pubmed-meshheading:2228313-Lymphocyte Activation,
pubmed-meshheading:2228313-Lymphoma,
pubmed-meshheading:2228313-Male,
pubmed-meshheading:2228313-Mice,
pubmed-meshheading:2228313-Mice, Inbred BALB C,
pubmed-meshheading:2228313-Mice, Transgenic,
pubmed-meshheading:2228313-Neoplasm Transplantation,
pubmed-meshheading:2228313-Plasmacytoma,
pubmed-meshheading:2228313-Retroviridae,
pubmed-meshheading:2228313-Spleen,
pubmed-meshheading:2228313-Terpenes,
pubmed-meshheading:2228313-Tumor Virus Infections
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Abelson murine leukemia virus transforms preneoplastic Emu-myc transgene-carrying cells of the B-lymphocyte lineage into plasmablastic tumors.
|
| pubmed:affiliation |
Department of Tumor Biology, Karolinska Institutet, Stockholm, Sweden.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|